drugset / Trial / NCT04634435
Autologous Memory-like NK Cell Therapy With BHV-1100 and Low Dose IL-2 in Multiple Myeloma Patients
NaSequentialOpen-labelTreatment
Summary
This is an open-label single center Phase 1a/1b study with the primary objective of establishing the safety and exploring the efficacy of infusing the ex vivo combination product of BHV-1100 plus cytokine induced memory-like (CIML) NK cells plus IVIG and low dose IL-2 in the peri-transplant setting in MM patients with minimal residual disease (MRD+) in first or second remission.
Timeline
- Start
- 2021-10-21
- Primary completion
- 2025-01-10
- Completion
- 2025-01-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CIML-NK Cells | Cell therapy | — | — |
| Subject | NORARAMTIDE | Protein / enzyme biologic | — | — |
| Background | Immune Globulin Intravenous (Human) | Protein / enzyme biologic | — | — |
| Background | aldesleukin | Protein / enzyme biologic | — | — |